On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
